Stifel Financial Corp Trims Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Stifel Financial Corp cut its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report) by 22.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 51,907 shares of the specialty pharmaceutical company’s stock after selling 15,182 shares during the period. Stifel Financial Corp owned 0.08% of Jazz Pharmaceuticals worth $6,385,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Cape Investment Advisory Inc. raised its holdings in Jazz Pharmaceuticals by 14,600.0% in the 4th quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock worth $36,000 after purchasing an additional 292 shares during the period. Covestor Ltd increased its position in Jazz Pharmaceuticals by 676.5% in the third quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company’s stock worth $51,000 after buying an additional 345 shares in the last quarter. Assetmark Inc. raised its stake in shares of Jazz Pharmaceuticals by 37.1% in the fourth quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 119 shares during the period. Spire Wealth Management lifted its position in shares of Jazz Pharmaceuticals by 128.6% during the 3rd quarter. Spire Wealth Management now owns 423 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 238 shares in the last quarter. Finally, Headinvest LLC bought a new position in shares of Jazz Pharmaceuticals during the 3rd quarter valued at approximately $56,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. JPMorgan Chase & Co. raised their target price on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an “overweight” rating in a research note on Friday, March 22nd. StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, May 31st. HC Wainwright reiterated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, May 3rd. UBS Group lowered their price objective on Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating on the stock in a research report on Friday, March 1st. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $195.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, February 29th. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $190.92.

Read Our Latest Stock Analysis on JAZZ

Jazz Pharmaceuticals Stock Up 5.4 %

Shares of JAZZ opened at $112.05 on Friday. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.27 and a quick ratio of 1.90. The stock has a market capitalization of $7.06 billion, a price-to-earnings ratio of 23.10, a price-to-earnings-growth ratio of 1.64 and a beta of 0.62. Jazz Pharmaceuticals plc has a 1 year low of $103.01 and a 1 year high of $146.70. The business’s 50 day simple moving average is $109.90 and its 200-day simple moving average is $117.76.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Free Report) last released its quarterly earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.53 by ($1.55). Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. The business had revenue of $901.98 million for the quarter, compared to analysts’ expectations of $938.99 million. As a group, equities analysts expect that Jazz Pharmaceuticals plc will post 15.35 earnings per share for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $109.65, for a total transaction of $548,250.00. Following the sale, the executive vice president now directly owns 36,629 shares of the company’s stock, valued at $4,016,369.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.40% of the stock is owned by insiders.

Jazz Pharmaceuticals Company Profile

(Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

See Also

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.